Physician profile
Robert Rasken
NPI 1679557672
$1,410.77
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $948 · 2021: $228.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $620.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $343.43 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $117.04 | 2019 | |
| Medtronic Vascular, INC. | $85.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $64.34 | 2020-2021 | |
| Pfizer INC. | $53.21 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $45.43 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $37.35 | 2019-2021 | |
| Amgen INC. | $26.02 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.63 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rasken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.